-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-520902-37-00
4
2026-04-01
Non-small cell lung cancer stage IV
-
2024-519550-36-00
6
2026-03-30
Allergic rhinoconjunctivitis
-
2024-519578-38-00
10
2026-03-30
Classic congenital adrenal hyperplasia
-
2023-503293-21-00
5
2026-03-25
Osteogenesis Imperfecta
-
2025-522892-27-00
4
2026-03-21
Bronchiectasis
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2025-522492-28-00
4
2026-03-13
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-523037-25-00
4
2026-03-10
Patients at high risk for Cardiac Surgery Associated – Acute Kidney In
-
2024-520222-11-00
3
2026-03-03
Hematological or solid tumor malignancies or autoimmune diseases
-
2025-521939-36-00
4
2026-03-03
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-522530-31-01
4
2026-02-27
Patients with metastatic PDAC, who have not progressed following compl
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-519068-42-00
10
2026-02-12
Heterozygous Familial Hypercholesterolemia in pediatric patients
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-522309-40-00
4
2026-02-11
Non-segmental vitiligo
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia